Researchers demonstrated that an enzyme that augments male hormones and metabolic difficulties – Type-2 diabetes and fatty liver disease – in women with Polycystic Ovary Syndrome (PCOS). The investigators originated that an enzyme, AKR1C3—that activates male hormone in the fat tissue of women with PCOS, has been recognized, which could increases the risk of metabolic health complications, counting Type-2 diabetes and fatty liver disease.
The enzyme “causes augmented activation of male hormones” in women with PCOS. Also to irregular periods and often damaged fertility, PCOS women repeatedly have elevated levels of male hormones, androgens, circulating in their blood.
These are known to cause difficulties with augmented male-pattern body hair development and acne. Women with PCOS often have superior levels of male hormones circulating in the blood and hormones in abdominal fat tissue far exceed those measured in their blood.
Lead study author Wiebke Arlt has also conveyed that the augmented activation of male hormones, which lead to enlarged build-up of lipid droplets in the fat cells and ultimately, to fatty acid overspill into the flow. Arlt further conveyed that the fat cells become less receptive and superior levels of insulin are produced. This augmented insulin then leads to even superior levels of AKR1C3.
Other researcher Dr Michael O’Reilly further noted that the study is mainly exciting because it highlights the role that body fat plays in generating excess male hormones in PCOS women, which then act locally to disturb the aptitude of the body’s fat to store lipid efficiently.